Therapy Center of Excellence

The Therapy Center of Excellence is dedicated to all aspects of the development and utilization of Targeted Radioisotope Therapy (TRT) as an alternative to other treatments. The Therapy Center is creating a multi-disciplinary interest group to share ideas, develop education offerings and advance the utilization of radionuclide therapy.

Mission

The Therapy Center of Excellence is an organizational component within the SNMMI dedicated to all aspects of the development and utilization of Targeted Radioisotope Therapy as an alternative to other treatments. Specifically, the new center will bring together a centralized group of all constituents within this area creating a multi-disciplinary interest group whereby industry, big pharma, physicians, scientists, government and regulatory agencies as well as other stakeholders can convene to share ideas, develop education offerings and advance the utilization of radionuclide therapy. 

The Therapy Center of Excellence:

(a)  Provides a forum for members with similar interests

(b)  Provides expertise in TRT

(c)  Fosters research and education in TRT

(d)  Provides outreach to other professionals and organizations

(e)  Nurtures new membership in SNMMI

 

Overview of Proposed Center of Excellence Activities

The center will focus on several initiatives, specific to the SNMMI Strategic Plan Goal C: Increase Appropriate Utilization of Radionuclide Therapy within the first year:

    Objective 1: Assist in the Development of Emerging Agents.

    Objective 2: Advocacy for Regulatory Approval and Reimbursement of Emerging Agents.

    Objective 3: Advanced the Use of Approved Agents.

 

 

Coming Soon!

The Saul Hertz, MD Award
SNMMI has established The Dr. Saul Hertz Lifetime Achievement Award in honor of the professional achievements of Dr. Hertz as the pioneer of Radioiodine Therapy. The award recognizes individuals who have made outstanding contributions to radionuclide therapy.

2019 Saul Hertz, MD Award Winner

2018 Saul Hertz, MD Award Winner

2017 Saul Hertz, MD Award Winner

2016 Saul Hertz, MD Award Winner

 

Therapy Center of Excellence Young Investigator Awards

The Therapy Center of Excellence is pleased to offer the Young Investigator Awards (YIAs) which are supported by grants from the Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF). 

2019 Young Investigator Awards

2018 Young Investigator Awards

2017 Young Investigator Awards

2016 Young Investigator Awards

SNMMI 2020 Mid-Winter Meeting

Save the date for the 2020 SNMMI Mid-Winter and ACNM Annual Meeting, January 23-25 in Tampa, Florida. The small, focused meeting environment and tailored learning approach will provide you with an ideal setting to further develop relevant skills and maximize tangible outcomes for your practice.

 

Therapy Center Sponsored Sessions at the SNMMI 2019 Annual Meeting

CAT08: Thyroid Cancer Theranostics - The Evolving Role for Nuclear Medicine in Clinical Genomics Paradigm

CE08: Prostate Cancer Nuts and Bolts: Diagnosis and Therapy

CE15: Differentiated Thyroid Cancer Theranostics Practicum

CE43: Current Uses of MIBG and New Directions

CE50: Saul Hertz Award Symposium: The Atomic Cocktail of Radioiodine Ushers in Precision Oncology

CE57: The Era of PRRT: Personalization, Integration and Future Perspectives

 

 

 

 

 

Membership Dues

Membership dues is $15 annually.

Member Benefits

Member benefits include:

 - Eligibility to vote in the Therapy COE Board of Directors elections

 - Newsletter

 - Sponsored educational symposia related to members’ interests

 - Therapy CoE E-Community

 - A $20.00 discount for Therapy CoE sponsored categorical session

 

Join The Therapy Center of Excellence 

- or -

Forward your request in writing with your check for annual center dues ($15) to SNMMI Membership Services, 1850 Samuel Morse Drive, Reston, VA 20190-5316. If you have any further questions about the Therapy Center of Excellence membership, please contact MemberInfo@snmmi.org



Announcements

2020 Saul Hertz, MD, Award

Deadline for submissions is October 15th!

 

Therapy Center of Excellence President

 


Dear TCOE Colleagues,

These are exciting times for those of us involved in radionuclide therapies.  Recently approved therapeutic radiopharmaceuticals for neuroendocrine tumors, pheochromocytoma/paraganglioma, and prostate cancer bone metastases have made treatment much more readily accessible, and patients no longer have to seek care available only at a handful of centers in the US.  These new therapies have also expanded the treatments offered by nuclear medicine physicians for thyroid cancer, B-cell lymphomas, bone metastases, and liver tumors.  With the VISION trial winding down, there is the prospect of both a new imaging agent and treatment for metastatic prostate cancer on the horizon, and additional trials hold promise for the further expansion of our therapeutic armamentarium.  Accordingly, there has been growing interest in the increasing relevance of radionuclide therapies for cancer patient management.

The Therapy Center leadership is working on your behalf in multiples ways.  First, we bring opportunities to learn about existing and innovative therapies from leaders in the field.  For instance, through the Committee on Radioiodine Theranostics (CORT) leadership, we have organized Categorical sessions on thyroid cancer at the Annual Meetings and regular Continuing Education sessions at both the Annual and Mid-Winter Meetings, as well as Categorical and CE sessions on other topics of interest.  We work to provide education about the clinical knowledge of the diseases, relevant imaging, and therapies as well as nuts and bolts sessions for implementing the newer therapies at your institutions.  The Therapeutics Conference in Las Vegas this month offers an additional in-person learning opportunity.  Finally, we are also working on virtual learning opportunities through webinars and online modules as additional educational resources.  

Since 2016, through the Saul Hertz Award Symposium, we recognize those in our field who have advanced radionuclide therapy in the manner of Dr. Saul Hertz, who was the first to conceive of and administer the ur-theranostic agent, radioactive iodine.  Past recipients include giants in our field: Drs. Steven Larson, George Sgouros, Richard Wahl, and Richard Baum.  Through the Young Investigators Award Symposium, we seek to identify the future innovators of radionuclide therapies.

We also promote the interests of the Center through collaboration with others.  Within the Society, we partner with other Councils and Centers to organize educational sessions such as the PETCOE, Pediatric Imaging, Correlative Imaging, and Radiopharmaceutical Science Councils as well as the Clinical Trials Network (CTN).   We are also engaging the Prostate Cancer Outreach Working Group as a body with interests that are aligned with that of the Therapy Center.  We also have and continue to work with the ABNM and ACNM as well as the American Society for Therapeutic Radiology and Oncology (ASTRO) to advocate for maintenance of training standards for Authorized User status with the NRC and its Advisory Committee on the Medical Uses of Isotopes (ACMUI) and to provide mutually relevant education for our respective memberships.  Lastly, in collaboration with the CTN and NCI, we are again gathering stakeholders from our Society, ASTRO, regulators, and industry for the Third Theranostics Conference at the NCI this December.

In addition to the positive developments in our field, we face a variety of challenges.  We need greater visibility and recognition for the entire field of nuclear medicine in general and of our roles in cancer patient management in particular.  Just as interventional oncologists have taken a seat at the table with medical, surgical and radiation oncologists, we need to take a seat as nuclear oncologists.  To that end, we need the clinical knowledge of an increasingly larger array of cancers and of relevant clinical trial data.  We need to advocate for the potential roles of radionuclide therapies to cure patients and to alleviate suffering.  We need to claim the training and experience that allows us to understand how nuclear imaging informs patient management.  Finally, we need innovators to create new therapeutic radiopharmaceuticals and investigators to design and conduct rigorous trials to explore additional indications for radionuclide therapy. 

I am privileged to serve as President of the Therapy Center of Excellence, and I am indebted to the support from my fellow officers, Society staff, and my fellow members.  Thank you all for your work on behalf of the Society and Therapy Center, and I invite your continued input to the Center leadership.  We depend on your engagement and active involvement so that we can work together and rise to challenges facing us.

 

Sincerely,

Dan Lee, MD
Therapy Center of Excellence, President